普罗布考治疗湿性年龄相关性黄斑变性的临床疗效

Clinical Effect of Probucol for Treatment of Exudative Aged-Related Macular Degeneration

目的观察口服普罗布考治疗湿性年龄相关性黄斑变性的临床疗效。方法选择2016年1月至2017年1月在开滦总医院林西医院经眼科裂隙灯检查、荧光素钠眼底血管造影(FFA)、光学相干断层扫描(OCT)确诊为湿性年龄相关性黄斑变性34例患者34只眼为研究对象,所有患者均接受0.5 g的普罗布考口服,每日2次。服药前均采用早期糖尿病视网膜病变治疗研究(ETDRS)视力表测量最佳矫正视力、行FFA及OCT检查,治疗后每月随访,随访6个月,每次除常规眼科检查外均行ETDRS视力及黄斑OCT检查,且分别于1、3、6个月行FFA检查。对比分析治疗前与治疗后不同时间点ETDRS视力、OCT黄斑中心凹厚度、FFA黄斑区渗出面积变化情况。结果服药后1、2、3、4、5、6个月所有患者的ETDRS视力均高于服药前(P<0.05),其中至随访终点时ETDRS视力提高≥15字母者12只眼(35%);服药后1、2、3、4、5、6个月所有患者的CMT厚度均低于治疗前(P<0.05);服药后1、3、6个月所有患者渗漏面积均低于治疗前(P<0.05)。随访期间未发现全身及眼部严重不良事件。结论口服普罗布考对湿性年龄相关性黄斑变性能起到较好的治疗作用且安全性好。

Objective To evaluate the clinical efficacy of oral administration of probucol in exudative aged-related macular degeneration.Methods This was a prospective study.There were 34 eyes of 34 patients with exudative aged-related macular degeneration included in the study.All patients were treated with probucol 0.5 g,twice a day.Before the study,best-corrected visual acuity of early treatment of diabetic retinopathy study(ETDRS),lit-lamp examination,fundus fluorescein angiograph(FFA),optical coherence tomography(OCT)examination were performed.The patients were followed for 6 months.ETDRS and OCT examination were done monthly.At first,third,sixth month,FFA examination were done.The ETDRS,central macular thickness(CMT),macular exudation areas were compared before and after treatment.Results At the first,second,third,fourth,fifth,sixth month,the ETDRS vision of all patients was higher than before(P<0.05).At the end of the follow-up,the ETDRS vision increased≥15 letters in 12 eyes(35%).At the first,second,third,fourth,fifth,sixth month,the CMT thickness of all patients was lower than before(P<0.05).At first,third sixth month,the macular exudation areas of all patients were lower than before(P<0.05).There were no serious systemic or ocular adverse events during the follow-up.Conclusion Oral administration of probucol for exudative aged-related macular degeneration shows good therapeutic effect and safety.